Xeno-Free Reprogramming of Peripheral Blood Mononuclear Erythroblasts on Laminin-521.


Journal

Current protocols in stem cell biology
ISSN: 1938-8969
Titre abrégé: Curr Protoc Stem Cell Biol
Pays: United States
ID NLM: 101470226

Informations de publication

Date de publication:
03 2020
Historique:
entrez: 25 1 2020
pubmed: 25 1 2020
medline: 11 6 2021
Statut: ppublish

Résumé

Translating human induced pluripotent stem cell (hiPSC)-derived cells and tissues into the clinic requires streamlined and reliable production of clinical-grade hiPSCs. This article describes an entirely animal component-free procedure for the reliable derivation of stable hiPSC lines from donor peripheral blood mononuclear cells (PBMCs) using only autologous patient materials and xeno-free reagents. PBMCs are isolated from a whole blood donation, from which a small amount of patient serum is also generated. The PBMCs are then expanded prior to reprogramming in an animal component-free erythroblast growth medium supplemented with autologous patient serum, thereby eliminating the need for animal serum. After expansion, the erythroblasts are reprogrammed using either cGMP-grade Sendai viral particles (CytoTune™ 2.1 kit) or episomally replicating reprogramming plasmids (Epi5™ kit), both commercially available. Expansion of emerging hiPSCs on a recombinant cGMP-grade human laminin substrate is compatible with a number of xeno-free or chemically defined media (some available as cGMP-grade reagents), such as E8, Nutristem, Stemfit, or mTeSR Plus. hiPSC lines derived using this method display expression of expected surface markers and transcription factors, loss of the reprogramming agent-derived nucleic acids, genetic stability, and the ability to robustly differentiate in vitro to multiple lineages. © 2020 by John Wiley & Sons, Inc. Basic Protocol 1: Isolating peripheral blood mononuclear cells using CPT tubes Support Protocol 1: Removal of clotting factors to produce serum from autologous plasma collected in Basic Protocol 1 Basic Protocol 2: PBMC expansion in an animal-free erythroblast expansion medium containing autologous serum Basic Protocol 3: Reprogramming of expanded PBMCs with Sendai viral reprogramming particles Alternate Protocol: Reprogramming of expanded PBMCs with episomal plasmids Basic Protocol 4: Picking, expanding, and cryopreserving hiPSC clones Support Protocol 2: Testing Sendai virus kit-reprogrammed hiPSC for absence of Sendai viral RNA Support Protocol 3: Testing Epi5 kit-reprogrammed hiPSC for absence of episomal plasmid DNA Support Protocol 4: Assessing the undifferentiated state of human pluripotent stem cell cultures by multi-color immunofluorescent staining and confocal imaging Support Protocol 5: Coating plates with extracellular matrices to support hiPSC attachment and expansion.

Identifiants

pubmed: 31977148
doi: 10.1002/cpsc.103
pmc: PMC7176073
mid: NIHMS1578341
doi:

Substances chimiques

Laminin 0
RNA, Viral 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e103

Subventions

Organisme : NIDDK NIH HHS
ID : U54 DK110805
Pays : United States

Informations de copyright

© 2020 John Wiley & Sons, Inc.

Références

Curr Protoc Stem Cell Biol. 2018 May;45(1):e48
pubmed: 30040234
Nature. 2017 May 11;545(7653):229-233
pubmed: 28445466
Adv Biochem Eng Biotechnol. 2018;163:1-21
pubmed: 29075799
Nat Biotechnol. 2006 Feb;24(2):185-7
pubmed: 16388305
Sci Rep. 2012;2:213
pubmed: 22355727
Cell. 2011 Feb 4;144(3):439-52
pubmed: 21295703
Biochemistry. 1986 Jan 28;25(2):312-8
pubmed: 2937447
Stem Cell Res Ther. 2018 Nov 8;9(1):307
pubmed: 30409192
Stem Cells. 2013 Mar;31(3):458-66
pubmed: 23193063
Cell Stem Cell. 2008 Dec 4;3(6):607-9
pubmed: 19041777
Sci Rep. 2014 Jan 08;4:3594
pubmed: 24399248
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Nat Biotechnol. 2001 Oct;19(10):971-4
pubmed: 11581665
Curr Protoc Stem Cell Biol. 2016 Aug 17;38:4A.9.1-4A.9.10
pubmed: 27532818
Regen Med. 2015 Nov;10(8):939-58
pubmed: 26345388
Nat Biotechnol. 2005 Jan;23(1):19-20
pubmed: 15637610
Stem Cell Rev Rep. 2016 Aug;12(4):394-420
pubmed: 27283945
Nat Methods. 2011 May;8(5):424-9
pubmed: 21478862
Curr Protoc Stem Cell Biol. 2007 Sep;Chapter 1:Unit 1C.2
pubmed: 18785163
Nat Biotechnol. 2015 Jan;33(1):58-63
pubmed: 25437882
Curr Protoc Stem Cell Biol. 2011 Dec;Chapter 1:Unit 1C.12
pubmed: 22135082
Curr Protoc Stem Cell Biol. 2015 Feb 02;32:1C.18.1-1C.18.8
pubmed: 25640816
Sci Rep. 2017 Jan 30;7:41165
pubmed: 28134277
Cloning Stem Cells. 2008 Mar;10(1):107-18
pubmed: 18241122
Stem Cell Reports. 2015 Oct 13;5(4):647-59
pubmed: 26411904
Nat Biotechnol. 2007 Jun;25(6):681-6
pubmed: 17529971
Nat Methods. 2011 May;8(5):409-12
pubmed: 21460823
Nat Protoc. 2014 Oct;9(10):2354-68
pubmed: 25211513
N Engl J Med. 2004 Mar 25;350(13):1353-6
pubmed: 14999088
Reprod Biol Endocrinol. 2015 Feb 22;13:9
pubmed: 25890180
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14234-9
pubmed: 21821793
PLoS One. 2015 Feb 25;10(2):e0118307
pubmed: 25714340
Sci Transl Med. 2019 Mar 6;11(482):
pubmed: 30842315
Nat Biotechnol. 2004 Apr;22(4):381-2; author reply 382
pubmed: 15060545
Nature. 2017 May 25;545(7655):432-438
pubmed: 28514439
Sci Rep. 2016 Jul 29;6:30742
pubmed: 27471043
J Clin Invest. 2015 Jul 1;125(7):2551-7
pubmed: 26132109
Curr Protoc Hum Genet. 2015 Oct 06;87:21.2.1-21.2.21
pubmed: 26439714

Auteurs

Christian Skorik (C)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Stemcell Technologies, Cambridge, Massachusetts.

Nathaniel K Mullin (NK)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Carver College of Medicine, University of Iowa, Iowa City, Iowa.

Michael Shi (M)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
School of Medicine, Case Western Reserve University, Cleveland, Ohio.

Yosra Zhang (Y)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Stemcell Technologies, Cambridge, Massachusetts.

Phoebe Hunter (P)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.

Yang Tang (Y)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.

Brianna Hilton (B)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.

Thorsten M Schlaeger (TM)

Stem Cell Core Facility, Boston Children's Hospital, Stem Cell Program, Boston, Massachusetts.
Harvard Stem Cell Institute, Boston, Massachusetts.
Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH